Windlas Biotech Ltd.
Fundamentals
- Market cap
- ₹1,773 cr
- P/E
- 26.67×
- ROE
- 12.06%
- Debt / equity
- 0.05
- Div yield
- 0.73%
- 52-week range
- 697.40 — 1097.90
Company snapshot
Windlas Biotech Ltd.
Pharmaceuticals
₹1,650 cr
P/E 24.73×
Latest quarter · Mar 2026
Sales₹238 cr
Net profit₹16 cr
Op. margin+10.6%
EPS₹7.58
Strength & growth
Debt / equity0.05×
Current ratio2.11×
The timeline — 4 notes on Windlas Biotech Ltd.
May 2026
- 22 May 26 · 1:54 PM IST Brief Brief · Concalls · Small cap
Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue
Regulatory action wiped out the company's codeine syrup business, while geopolitical tension and solvent costs weigh on margins.
- 21 May 26 · 5:39 PM IST Brief Brief · Earnings · Small cap
Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.
Q4/FY26 results show 19% revenue growth and 31% PAT growth, but these numbers were disclosed in earlier filings. Real story: 13th consecutive record quarter and Plant-6 on track.
- 21 May 26 · 4:54 PM IST Brief Brief · Earnings · Small cap
Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26
Revenue grew 19% to ₹9,041M; profit touched ₹664M. Both numbers were in line with expectations.
- 21 May 26 · 4:34 PM IST Brief Brief · Earnings · Small cap
Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30
Revenue grew 19% to ₹9,041 mn, net profit rose 9% to ₹664 mn. Results were widely anticipated with no material surprises.